Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premedication for prevention of acute adverse effects during IVIG infusion
IRCT20210206050268N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-blind trial of methylprednisolone, naproxen and immune globulin in neurological diseases (3 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Acute adverse effects after IVIG administration, Vital sign abnormalities and 1 more. Started Jan 2022; status: completed.
02
Drugs
methylprednisolonenaproxenimmune globulin
03
Conditions
neurological diseases
Beyond the preview
Go deeper on IRCT20210206050268N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210206050268N1.